Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial

IMPORTANCE: A high 21-gene recurrence score (RS) by breast cancer assay is prognostic for distant recurrence of early breast cancer after local therapy and endocrine therapy alone, and for chemotherapy benefit. OBJECTIVE: To describe clinical outcomes for women with a high RS who received adjuvant c...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:JAMA Oncol
Hoofdauteurs: Sparano, Joseph A., Gray, Robert J., Makower, Della F., Albain, Kathy S., Saphner, Thomas J., Badve, Sunil S, Wagner, Lynne I., Kaklamani, Virginia G., Keane, Maccon M., Gomez, Henry L., Reddy, Pavan S., Goggins, Timothy F., Mayer, Ingrid A., Toppmeyer, Deborah L., Brufsky, Adam M., Goetz, Matthew P., Berenberg, Jeffrey L., Mahalcioiu, Catalin, Desbiens, Christine, Hayes, Daniel F., Dees, Elizabeth C., Geyer, Charles E., Olson, John A., Wood, William C, Lively, Tracy, Paik, Soonmyung, Ellis, Matthew J., Abrams, Jeffrey, Sledge, George W.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Medical Association 2019
Onderwerpen:
Original Investigation
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6777230/
https://ncbi.nlm.nih.gov/pubmed/31566680
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.4794
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items